wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36490256-6683AB57-E595-4BDA-9FD7-50EED88A3BBF
Q36490256-6683AB57-E595-4BDA-9FD7-50EED88A3BBF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36490256-6683AB57-E595-4BDA-9FD7-50EED88A3BBF
Therapeutic targeting of the inflammome.
P2860
Q36490256-6683AB57-E595-4BDA-9FD7-50EED88A3BBF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36490256-6683AB57-E595-4BDA-9FD7-50EED88A3BBF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
223ee716fc04e1dc959b1acb0a36a89b190e32ea
P2860
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients